KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in KalVista Pharmaceuticals by 154.5%, now holding 39,804 shares worth approximately $459,000 as of the latest SEC disclosure.
• Wall Street analysts have raised their price targets for KalVista, with HC Wainwright and JMP Securities both increasing their target to $27.00, reflecting a positive outlook on the company's performance.
• CEO Benjamin L. Palleiko sold 32,979 shares of the company at an average price of $15.69, resulting in an 8.19% decrease in his ownership position.

Invesco Ltd. grew its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 154.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,804 shares of the specialty pharmaceutical company's stock after purchasing an additional 24,164 shares during the quarter. Invesco Ltd. owned approximately 0.08% of KalVista Pharmaceuticals worth $459,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Rhumbline Advisers grew its position in shares of KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after purchasing an additional 1,762 shares during the period. GAMMA Investing LLC grew its position in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 3,767 shares during the period. Bank of America Corp DE grew its position in shares of KalVista Pharmaceuticals by 108.8% in the fourth quarter. Bank of America Corp DE now owns 110,050 shares of the specialty pharmaceutical company's stock valued at $932,000 after purchasing an additional 57,356 shares during the period. ProShare Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $101,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $452,000.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock traded down $0.58 on Thursday, reaching $14.81. The company had a trading volume of 2,891,120 shares, compared to its average volume of 791,340. The firm's 50 day moving average price is $14.10 and its two-hundred day moving average price is $12.77. The firm has a market cap of $745.54 million, a PE ratio of -4.01 and a beta of -0.10. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.21). The firm had revenue of $1.43 million for the quarter, compared to analyst estimates of $1.97 million. As a group, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Wall Street Analyst Weigh In

KALV has been the topic of several research analyst reports. HC Wainwright lifted their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Leerink Partners raised their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, July 7th. Finally, JMP Securities lifted their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $26.29.

Insider Buying and Selling

In other news, insider Paul K. Audhya sold 2,336 shares of the business's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $13.42, for a total value of $31,349.12. Following the sale, the insider directly owned 122,505 shares of the company's stock, valued at approximately $1,644,017.10. The trade was a 1.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,294 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $15.84, for a total transaction of $115,536.96. Following the completion of the sale, the chief executive officer directly owned 395,189 shares in the company, valued at $6,259,793.76. This trade represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,835 shares of company stock worth $892,350 over the last three months. Insiders own 4.30% of the company's stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).